Israel’s Immunai has used its immune system AI mapping platform to discover a novel therapeutic target for inflammatory bowel disease (IBD). Immunai has partnered with AstraZeneca who will develop the therapy, which if successful will earn Immunai up to $85 million.
IBD therapy discovered
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.